HRP20211290T1 - Sinteza omekamtiv mekarbila - Google Patents

Sinteza omekamtiv mekarbila Download PDF

Info

Publication number
HRP20211290T1
HRP20211290T1 HRP20211290TT HRP20211290T HRP20211290T1 HR P20211290 T1 HRP20211290 T1 HR P20211290T1 HR P20211290T T HRP20211290T T HR P20211290TT HR P20211290 T HRP20211290 T HR P20211290T HR P20211290 T1 HRP20211290 T1 HR P20211290T1
Authority
HR
Croatia
Prior art keywords
pmec
fnb
image
mixing
phosphate hydrate
Prior art date
Application number
HRP20211290TT
Other languages
English (en)
Inventor
Sebastien Caille
Kyle QUASDORF
Philipp ROOSEN
Xianqing Shi
Andrew COSBIE
Fang Wang
Zufan WU
Archana NEERGUNDA
Bin Peter Quan
Lianxiu GUAN
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HRP20211290T1 publication Critical patent/HRP20211290T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Claims (14)

1. Piperazin metil karboksilat fosfat hidrat [image] („PMEC“).
2. Postupak za sintetiziranje piperazin metil karboksilat [image] („PMEC“) fosfat hidrata, naznačen time, da obuhvaća: (a) miješanje piperazina i metil kloroformata u svrhu tvorbe PMEC; (b) miješanje PMEC i 0,5 molarnih ekvivalenata fosforne kiseline u vodenoj otopini u svrhu tvorbe PMEC fosfat hidrata; i (c) opcionalno filtriranje PMEC fosfat hidrata iz smjese u koraku (b).
3. Postupak prema patentnom zahtjevu 2, naznačen time, da nadalje obuhvaća izoliranje PMEC stvorenog u koraku (a) kao otopine u metilen kloridu, dikloretanu, 2-metiltetrahidrofuranu, ili njihovoj mješavini.
4. Postupak prema patentnom zahtjevu 3, naznačen time, da se izoliranje provodi putem (i) ispiranja dobivenog PMEC iz koraka (a) s organskim otapalom; (ii) modificiranja pH vrijednosti na 8 do 14 dodavanjem baze u svrhu tvorbe bazične vodene otopine; i (iii) ekstrahiranja PMEC iz bazične vodene otopine iz koraka (ii) s metilen kloridom, dikloretanom, 2-metil tetrahidrofuranom, ili njihovom mješavinom.
5. Postupak prema patentnom zahtjevu 2, naznačen time, da se korak (a) provodi u vodenoj otopini.
6. Postupak prema bilo kojem od patentnih zahtjeva 2 do 5, naznačen time, da se korak (a) provodi na temperaturi od 20 do 55 °C u vremenu od 1 do 12 sati.
7. Postupak za sintetiziranje metil 4-(2-fluoro-3-nitrobenzil)piperazin-1-karboksilata [image] (PIPN), naznačen time, da obuhvaća (a) miješanje 2-fluoro-3-nitrotoluena, natrijevog bromata i natrijevog bisulfita u izopropilacetatu i vodi u svrhu tvorbe 1-(bromometil)-2-fluoro-3-nitrobenzena [image] (FNB); (b) opcionalno ispiranje FNB s vodenim natrijevim tiosulfatom, s vodenim natrijevim kloridom, ili s oba; i (c) miješanje FNB, trialkilaminske baze i piperazin metil karboksilat [image] („PMEC“) fosfat hidrata u svrhu tvorbe PIPN.
8. Postupak prema patentnom zahtjevu 7, naznačen time, da se FNB ispire s vodenim natrijevim tiosulfatom i vodenim natrijevim kloridom.
9. Postupak za sintetiziranje metil 4-(2-fluoro-3-nitrobenzil)piperazin-1-karboksilata [image] (PIPN), naznačen time, da obuhvaća: (a) miješanje 2-fluoro-3-nitrotoluena, benzoil peroksida, N-bromosukcinimida i octene kiseline na temperaturi od 70 do 95 °C u svrhu tvorbe 1-(bromometil)-2-fluoro-3-nitrobenzena [image] (FNB); (b) opcionalno ekstrahiranje FNB s toluenom, ispiranje FNB s vodenom bazičnom otopinom, ili oboje; (c) miješanje FNB, trialkilaminske baze i piperazin metil karboksilat [image] („PMEC“) fosfatnog hidrata u svrhu tvorbe PIPN.
10. Postupak prema patentnom zahtjevu 9, naznačen time, da se FNB ekstrahira s toluenom i ispire s vodenim natrijevim hidroksidom.
11. Postupak prema bilo kojem od patentnih zahtjeva 7 do 10, naznačen time, da se PIPN tvori kao hidrokloridna sol.
12. Postupak prema bilo kojem od patentnih zahtjeva 7 do 11, naznačen time, da se PMEC fosfat hidrat pripravlja putem postupka prema bilo kojem od patentnih zahtjeva 2 do 6.
13. Postupak prema bilo kojem od patentnih zahtjeva 7 do 12, naznačen time, da trialkilaminska baza sadrži diizopropiletilamin ili trietilamin.
14. Postupak prema bilo kojem od patentnih zahtjeva 7 do 13, naznačen time, da prije miješanja FNB, trialkilaminske baze i PMEC fosfat hidrata, postupak nadalje obuhvaća dodavanje dietilfosfita i trialkilamina, i miješanje rezultirajuće smjese na temperaturi od 30 do 65 °C.
HRP20211290TT 2017-06-30 2021-08-11 Sinteza omekamtiv mekarbila HRP20211290T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762527174P 2017-06-30 2017-06-30
US201862664363P 2018-04-30 2018-04-30
EP18743314.9A EP3645518B1 (en) 2017-06-30 2018-06-29 Synthesis of omecamtiv mecarbil
PCT/US2018/040176 WO2019006231A1 (en) 2017-06-30 2018-06-29 SYNTHESIS OF OMECAMTIV MECARBIL

Publications (1)

Publication Number Publication Date
HRP20211290T1 true HRP20211290T1 (hr) 2021-11-12

Family

ID=62976317

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211290TT HRP20211290T1 (hr) 2017-06-30 2021-08-11 Sinteza omekamtiv mekarbila

Country Status (27)

Country Link
US (3) US11040956B2 (hr)
EP (3) EP3925950B1 (hr)
JP (2) JP7181896B2 (hr)
KR (1) KR102625774B1 (hr)
CN (1) CN110799503B (hr)
AU (1) AU2018294254C1 (hr)
BR (1) BR112019028205A2 (hr)
CA (1) CA3063102A1 (hr)
CL (2) CL2019003898A1 (hr)
CY (1) CY1124427T1 (hr)
DK (1) DK3645518T3 (hr)
ES (1) ES2882905T3 (hr)
GE (1) GEP20227340B (hr)
HR (1) HRP20211290T1 (hr)
HU (1) HUE055242T2 (hr)
IL (2) IL294834A (hr)
LT (1) LT3645518T (hr)
MD (1) MD3645518T2 (hr)
MX (2) MX2021013326A (hr)
PL (1) PL3645518T3 (hr)
PT (1) PT3645518T (hr)
RS (1) RS62328B1 (hr)
SG (1) SG10202111790YA (hr)
SI (1) SI3645518T1 (hr)
TW (2) TWI769272B (hr)
UA (1) UA127517C2 (hr)
WO (1) WO2019006231A1 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970123T3 (da) 2013-03-14 2019-10-21 Amgen Inc Salt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
PT3645518T (pt) 2017-06-30 2021-08-23 Amgen Inc Síntese de omecamtiv mecarbil
TWI790281B (zh) 2017-09-13 2023-01-21 美商安進公司 雙醯胺肌節活化化合物及其用途
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
WO2021070123A1 (en) * 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
WO2021070124A1 (en) * 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CN117157274A (zh) 2021-03-10 2023-12-01 安进股份有限公司 奥美卡替莫卡必尔的合成
WO2023205291A2 (en) * 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
DE602007011793D1 (de) * 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
US20120083476A1 (en) * 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
DK2970123T3 (da) 2013-03-14 2019-10-21 Amgen Inc Salt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf
EP3127564B1 (en) 2014-03-31 2018-12-26 Med-tech Inc. Blood purification device and priming method for blood purification device
TW201625568A (zh) * 2014-11-24 2016-07-16 歌林達有限公司 作爲類香草素受體之配位體ii之經取代以噁唑及噻唑爲主之甲醯胺及脲衍生物
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
PT3645518T (pt) 2017-06-30 2021-08-23 Amgen Inc Síntese de omecamtiv mecarbil
ES2815899T3 (es) 2018-07-09 2021-03-31 Fis Fabbrica Italiana Sintetici Spa 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
US20220042055A1 (en) 2018-12-18 2022-02-10 Amgen Inc. Method of reducing aromatic nitro compounds
WO2021070124A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
JP2023513249A (ja) 2020-02-10 2023-03-30 アムジェン インコーポレイテッド オメカムチブメカルビル製剤
AU2021380754A1 (en) 2020-11-12 2023-06-22 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
CN117157274A (zh) 2021-03-10 2023-12-01 安进股份有限公司 奥美卡替莫卡必尔的合成

Also Published As

Publication number Publication date
AU2018294254A1 (en) 2019-11-21
ES2882905T3 (es) 2021-12-03
US20210371397A1 (en) 2021-12-02
CL2021002167A1 (es) 2022-03-18
JP2020526476A (ja) 2020-08-31
EP3645518B1 (en) 2021-05-19
CY1124427T1 (el) 2022-07-22
AU2018294254B2 (en) 2022-04-07
SI3645518T1 (sl) 2021-11-30
RS62328B1 (sr) 2021-10-29
SG10202111790YA (en) 2021-12-30
BR112019028205A2 (pt) 2020-10-06
US20200308143A1 (en) 2020-10-01
US20230373955A1 (en) 2023-11-23
GEP20227340B (en) 2022-01-25
WO2019006231A1 (en) 2019-01-03
EP4265597A3 (en) 2023-11-22
JP2022166243A (ja) 2022-11-01
KR20200018664A (ko) 2020-02-19
TW202235415A (zh) 2022-09-16
LT3645518T (lt) 2021-10-11
IL294834A (en) 2022-09-01
EP3925950A1 (en) 2021-12-22
IL270663A (hr) 2020-01-30
TWI769272B (zh) 2022-07-01
IL270663B (en) 2022-08-01
HUE055242T2 (hu) 2021-11-29
CA3063102A1 (en) 2019-01-03
KR102625774B1 (ko) 2024-01-16
EP3925950B1 (en) 2023-09-06
CN110799503B (zh) 2023-06-27
PT3645518T (pt) 2021-08-23
MX2021009594A (es) 2022-10-24
JP7181896B2 (ja) 2022-12-01
EP3645518A1 (en) 2020-05-06
MD3645518T2 (ro) 2021-11-30
PL3645518T3 (pl) 2021-12-06
CN110799503A (zh) 2020-02-14
UA127517C2 (uk) 2023-09-20
TW201906826A (zh) 2019-02-16
AU2018294254C1 (en) 2022-10-13
US11040956B2 (en) 2021-06-22
AU2022204648A1 (en) 2022-07-28
US11753394B2 (en) 2023-09-12
EP3925950C0 (en) 2023-09-06
DK3645518T3 (en) 2021-08-02
EP4265597A2 (en) 2023-10-25
CL2019003898A1 (es) 2020-07-31
MX2021013326A (es) 2022-08-11

Similar Documents

Publication Publication Date Title
HRP20211290T1 (hr) Sinteza omekamtiv mekarbila
TWI554507B (zh) 藉由苯并酮與胺反應製備經四唑取代之鄰胺苯甲酸二醯胺衍生物的方法
AR107633A1 (es) Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
ATE491712T1 (de) Verfahren zur stabilisierung von thiophenderivaten
NO20075532L (no) Fremgangsmater for fremstilling av metylglycin-N,N-dietansyre-trialkali metall salter med et lavt innhold av biprodukt
NO20063452L (no) Benzamid-derivater og deres anvendelse som glukokinaseaktiversingsmidler
RU2015106856A (ru) Способ получения производных пиразолкарбоновой кислоты
DE602005017197D1 (de) Verbessertes verfahren zur herstellung von cefixim
RU2016135762A (ru) Способ получения (r)-1,1,3-триметил-4-аминоиндана
EA200901175A1 (ru) Способ получения 2,6-дихлор-4-(трифторметил)фенилгидразина, используя смеси дихлор-фтор-трифторметилбензолов
ATE423778T1 (de) Verfahren zur herstellung von anthranilsäurederivat-hydrat
PH12019501491A1 (en) Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide
NO20062492L (no) Fremgangsmate for fremstilling av tubulininhibitorer
JP2016503812A5 (hr)
WO2016027283A4 (en) A process for preparing indacaterol and salts thereof
CN105175331A (zh) 一种egfr类分子靶向抗肿瘤药物的制备方法
CN105980360A (zh) 2-酰基亚胺吡啶衍生物的制造方法
EA201171467A1 (ru) Способ получения композиции, содержащей антивинную кислоту
JP2018536654A5 (hr)
NZ751777A (en) Pharmaceutical composition and methods of uses
CN104876865A (zh) 一种博舒替尼的制备工艺
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
DE602007013063D1 (de) Verfahren zur herstellung quaternärer alkylammoniumhalide
JP2016539994A5 (hr)
KR101590106B1 (ko) 1-옥사세팔로스포린 유도체의 제조방법